Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

Diabetologia

Volumn 40, Issue 2, 1997, Pages 205-211

  Rachman, J ^a,b   Barrow, B A ^a   Levy, J C ^a   Turner, R C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Beta cell function; Glucagon like peptide 1; Glucose concentrations; Non insulin dependent diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STOMACH EMPTYING;

ADULT; AGED; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; FEMALE; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS;

EID: 0031033531     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050664     Document Type: Article

References (37)

1. DeFronzo RA (1988) The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687
2. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC (1985) Sulphonylurea therapy doubles β-cell responses to glucose in type 2 diabetic patients. Diabetologia 28: 809-814
3. UK Prospective Diabetes Study 16 (1995) Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258
4. Holman RR, Turner RC (1978) Basal normoglycemia attained with chlorpropamide in mild diabetes. Metabolism 27: 539-547
5. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52
6. Creutzfeld W (1979) The incretin concept today. Diabetologia 16: 75-85
7. Kreymann B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide-1: a physiological incretin in man. Lancet 1300-1303
8. Nauck MA; Bartels E, Ørskov C, Ebert R, Creutzfeld W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917
9. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261: 11880-11889
10. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ (1989) Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 264: 12826-12829
11. Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW (1987) Truncated glucagon-like peptide 1, and insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174
12. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide 1 (7-37) coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619
13. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagonlike peptide 1 (7-37) actions on endocrine pancreas. Diabetes 38: 338-342
14. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744
15. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide-1 (7-36) amide in patients with NIDDM. Diabetes 45: 1524-1530
16. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
17. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17: 1039-1044
18. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
19. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1990) Truncated GLP-1 (proglucagon 78-107-amide) from distal gut: role in regulation of gastric and pancreatic functions. Digestion 46 [Suppl 1]: 335 (Abstract)
20. Fehmann H-C, Göke R, Göke B, Bächle R, Wagner B, Arnold R (1991) Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochem Biophys Acta 1091: 356-363
21. Holz GG, Kühtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulino-tropic hormone glucagon-like peptide-1 (7-37). Nature 361: 362-365
22. UK Prospective Diabetes Study (UKPDS) XI (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11: 534-554
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419
24. Jackson RA, Hawa MI, Jaspan JB et al. (1987) Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 36: 632-640
25. Chiasson J-L, Josse RG, Hunt JA et al. (1994) The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928-935
26. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266
27. D'Alessio DA, Prigeon RL, Ensinck JW (1995) Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide 1. Diabetes 44: 1433-1437
28. Komatsu R, Matsuyama T, Namba M et al. (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide 1-(7-36)-amide. Diabetes 38: 902-905
29. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38: 720-725
30. Ørskov C, Wettergren A, Poulsen SS, Holst JJ (1995) Is the effect of glucagon-like peptide-1 on gastric emptying centrally mediated? Diabetologia 38 [Suppl 1]: A39 (Abstract)
31. Kanse SM, Kreymann B, Ghatei MA, Bloom SR (1988) Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett 241: 209-212
32. Thorens B, Porret A, Bühler L, Deng S-P, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682
33. Dillon JS, Tanizawa Y, Wheeler MB et al. (1993) Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133: 1907-1910
34. 2+ channel activity. Endocrinology 133: 1685-1692
35. 2+-signaling pathway in pancreatic β-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270: 17749-17757
36. Ämmälä C, Ashcroft FM, Rorsman P (1993) Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature 363: 356-358
37. Larsen J, Jallad N, Damsbo P (1989) One-week continuous infusion of GLP-1 (7-37) improves the glycaemic control in NIDDM. Diabetes 45 [Suppl 2]: 232A (Abstract)